Journal of medical Internet research · 2026
Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Johnson Hans, Clift Ashley Kieran, Reisel Daniel, Huang David
Аннотация
BACKGROUND: The advent of tirzepatide has transformed obesity care; yet, real-world weight loss outcomes necessarily depend on patient engagement with behavioral support. Digital platforms offering coaching, self-monitoring, and automated feedback have the potential to further augment pharmacological efficacy.
OBJECTIVE: The aim of the study is to examine associations between digital engagement and weight loss outcomes among adults prescribed tirzepatide in routine care over 12 months and to identify baseline correlates of engagement.
METHODS: In this retrospective cohort study, we included adults (18-75 years; BMI ≥30 or ≥27.5 kg/m2 with comorbidities) who initiated tirzepatide between February 2024 and August 2025 via a UK digital weight loss service. Engagement was defined by all 3: attendance at ≥1 coaching session AND ≥1 weekly weight log AND ≥1 app login over 12 months. Percent weight loss was analyzed at months 2, 4, 6, 8, 10, and 12 using a mixed model repeated measures adjusted for age, sex, baseline BMI, and comorbidities. Time-to-event analyses (Kaplan-Meier) assessed attainment of ≥5%, ≥10%, ≥15%, and ≥20% weight loss thresholds. Multivariable logistic regression identified correlates of engagement, reporting odds ratios (ORs) per decade of age and per 5 kg/m2 BMI.
RESULTS: Among 126,553 participants, 6746 (5.3%) were maximally engaged. Cohort demographics were a mean age of 42.3 (SD 12.4) years, 78.9% (99,905/126,553) female, and a mean BMI of 35.3 (SD 6.2) kg/m2. Engaged users achieved greater adjusted weight loss at month 12 (-22.9%, 95% CI -23.2 to -22.6) versus nonengaged users (-17.5%, 95% CI -17.7 to -17.4), an absolute difference of 5.3 percentage points (P<.001; Cohen d=0.54). Differences emerged by month 2 (-7.4% vs -6.4%; P<.001) and widened steadily. Engaged participants reached all clinically significant weight loss thresholds faster (5%-20%; log-rank P<.001), and engaged participants were nearly 3 times more likely to achieve ≥20% weight loss compared to nonengaged participants (1079/6746, 16% vs 6710/119,807, 5.6%; risk ratio 2.88; P<.001). Older age (OR 1.18 per decade, 95% CI 1.15-1.20; P<.001), higher BMI (OR 1.14 per 5 kg/m2, 95% CI 1.12-1.16; P<.001), and the presence of polycystic ovary syndrome (OR 1.59, 95% CI 1.45-1.74; P<.001) or fatty liver disease (OR 1.52, 95% CI 1.32-1.76; P<.001) correlated with engagement. Male sex (OR 0.86, 95% CI 0.81-0.92; P<.001) and diabetes (OR 0.83, 95% CI 0.73-0.95; P=.009) were associated with lower engagement.
CONCLUSIONS: Digital engagement was associated with substantially greater tirzepatide-associated weight loss in real-world practice. Integrating structured digital support with pharmacotherapy represents a promising strategy for optimizing obesity management.
OBJECTIVE: The aim of the study is to examine associations between digital engagement and weight loss outcomes among adults prescribed tirzepatide in routine care over 12 months and to identify baseline correlates of engagement.
METHODS: In this retrospective cohort study, we included adults (18-75 years; BMI ≥30 or ≥27.5 kg/m2 with comorbidities) who initiated tirzepatide between February 2024 and August 2025 via a UK digital weight loss service. Engagement was defined by all 3: attendance at ≥1 coaching session AND ≥1 weekly weight log AND ≥1 app login over 12 months. Percent weight loss was analyzed at months 2, 4, 6, 8, 10, and 12 using a mixed model repeated measures adjusted for age, sex, baseline BMI, and comorbidities. Time-to-event analyses (Kaplan-Meier) assessed attainment of ≥5%, ≥10%, ≥15%, and ≥20% weight loss thresholds. Multivariable logistic regression identified correlates of engagement, reporting odds ratios (ORs) per decade of age and per 5 kg/m2 BMI.
RESULTS: Among 126,553 participants, 6746 (5.3%) were maximally engaged. Cohort demographics were a mean age of 42.3 (SD 12.4) years, 78.9% (99,905/126,553) female, and a mean BMI of 35.3 (SD 6.2) kg/m2. Engaged users achieved greater adjusted weight loss at month 12 (-22.9%, 95% CI -23.2 to -22.6) versus nonengaged users (-17.5%, 95% CI -17.7 to -17.4), an absolute difference of 5.3 percentage points (P<.001; Cohen d=0.54). Differences emerged by month 2 (-7.4% vs -6.4%; P<.001) and widened steadily. Engaged participants reached all clinically significant weight loss thresholds faster (5%-20%; log-rank P<.001), and engaged participants were nearly 3 times more likely to achieve ≥20% weight loss compared to nonengaged participants (1079/6746, 16% vs 6710/119,807, 5.6%; risk ratio 2.88; P<.001). Older age (OR 1.18 per decade, 95% CI 1.15-1.20; P<.001), higher BMI (OR 1.14 per 5 kg/m2, 95% CI 1.12-1.16; P<.001), and the presence of polycystic ovary syndrome (OR 1.59, 95% CI 1.45-1.74; P<.001) or fatty liver disease (OR 1.52, 95% CI 1.32-1.76; P<.001) correlated with engagement. Male sex (OR 0.86, 95% CI 0.81-0.92; P<.001) and diabetes (OR 0.83, 95% CI 0.73-0.95; P=.009) were associated with lower engagement.
CONCLUSIONS: Digital engagement was associated with substantially greater tirzepatide-associated weight loss in real-world practice. Integrating structured digital support with pharmacotherapy represents a promising strategy for optimizing obesity management.